SERA PROGNOSTICS, INC. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Sera Prognostics reported Q3 2026 revenue of $42K (163% YoY increase), with PreTRM test volume up 54% sequentially and ~5x from Q1 2026. Florida added PreTRM to its Medicaid fee schedule (covering ~90K Medicaid births/year), joining Illinois as the second state with Medicaid coverage, bringing total covered Medicaid lives to ~7M. The company has $72.8M in cash/securities (down from $91.8M at year-end 2025 due to $22.4M operating cash burn YTD), burned $7.3M operationally in Q3, and is pursuing CE Mark submission for European commercialization and a multi-thousand-patient pilot with a major commercial insurer in FY2027.
Why this rating
Strong operational momentum (5x volume growth, second state Medicaid win) validates strategy, but $42K quarterly revenue is immaterial; cash burn of $7.3M/quarter against $72.8M reserves (~10 quarters runway) creates medium-term urgency. Material for early-stage biotech, but not yet transformational.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.